Enlivex Ltd.
Business
Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company developing Allocetra™, an off-the-shelf cell therapy that reprograms macrophages to restore immune homeostasis. It focuses on Allocetra™ as its primary product candidate for inflammatory and life‑threatening conditions, including osteoarthritis and sepsis, delivered via intra‑articular injections or intravenous infusions. The company conducts clinical development, cGMP manufacturing of frozen Allocetra™, and manages intellectual property and CRO collaborations. Enlivex runs multi‑center trials in Israel, Europe and the U.S. and plans commercialization via strategic partnerships and licensing.
Summary from filing dated 2025-04-30
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $1.24B |
| Total assets | $2.33B |
| Total liabilities | $392.05M |
| Stockholders' equity | $1.93B |
| Operating cash flow | $-10.42M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Enlivex Ltd.'s CIK number?
Enlivex Ltd.'s SEC CIK number is 0001596812 (1596812). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Enlivex Ltd.'s SEC filings?
All of Enlivex Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.